We develop a medicinal product with fosfomycin trometamol. Impurity A increases greatly - at a rate of 0.3, 1.5 results in accelerated conditions. The product consists of fosfomycin 5.631 grams + 5 grams of sucrose + orange flavor. What can be attributed to this increase in impurity A?